The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Abstract
Purpose: Mutations within the KRAS proto-oncogene have predictive value but are of uncertain prognostic value in the treatment of advanced colorectal cancer. We took advantage of PETACC-3, an adjuvant trial with 3,278 patients with stage II to III colon cancer, to evaluate the prognostic value of KRAS and BRAF tumor mutation status in this setting. Patients and Methods: Formalin-fixed paraffin-embedded tissue blocks (n = 1,564) were prospectively collected and DNA was extracted from tissue sections from 1,404 cases. Planned analysis of KRAS exon 2 and BRAF exon 15 mutations was performed by allele-specific real-time polymerase chain reaction. Survival analyses were based on univariate and multivariate proportional hazard regression models. Results: KRAS and BRAF tumor mutation rates were 37.0% and 7.9%, respectively, and were not significantly different according to tumor stage. In a multivariate analysis containing stage, tumor site, nodal status, sex, age, grade, and microsatellite instability (MSI) status, KRAS mutation was associated with grade (P = .0016), while BRAF mutation was significantly associated with female sex (P = .017), and highly significantly associated with right-sided tumors, older age, high grade, and MSI-high tumors (all P < 10−4). In univariate and multivariate analysis, KRAS mutations did not have a major prognostic value regarding relapse-free survival (RFS) or overall survival (OS). BRAF mutation was not prognostic for RFS, but was for OS, particularly in patients with MSI-low (MSI-L) and stable (MSI-S) tumors (hazard ratio, 2.2; 95% CI, 1.4 to 3.4; P = .0003). Conclusion: In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value. BRAF is prognostic for OS in MS-L/S tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Self-citationThe Interpretation of Random-Effects Meta-Analysis in Decision Models
Ades, A. E., Lu, G., & Higgins, J. P. T. (2005) · Medical Decision Making · doi:10.1177/0272989x05282643 · Cited by 859
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M., Giovannucci, E. L., & Fuchs, C. S. (2009) · Gut · doi:10.1136/gut.2008.155473 · Cited by 777
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Self-citationPoor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers
Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0404 · Cited by 737
Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Topham, C., Tabernero, J., André, T., Sobrero, A. F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6663 · Cited by 467
Self-citationAssociation between chromosomal instability and prognosis in colorectal cancer: a meta-analysis
Walther, A., Houlston, R., & Tomlinson, I. (2008) · Gut · doi:10.1136/gut.2007.135004 · Cited by 368
Genomic instability and colon cancer
Grady, W. M. (2004) · Cancer and Metastasis Reviews · doi:10.1023/a:1025861527711 · Cited by 353
Barault, L., Veyrie, N., Jooste, V., Lecorre, D., Chapusot, C., Ferraz, J., Lièvre, A., Cortet, M., Bouvier, A., Rat, P., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23388 · Cited by 331
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
Fransen, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh049 · Cited by 268
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
Conlin, A., Smith, G., Carey, F. A., Wolf, C. R., & Steele, R. J. C. (2005) · Gut · doi:10.1136/gut.2005.066514 · Cited by 261
Rosenberg, D. W., Yang, S., Pleau, D. C., Greenspan, E. J., Stevens, R. G., Rajan, T. V., Heinen, C. D., Levine, J., Zhou, Y., & O'Brien, M. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0343 · Cited by 171
Ikenoue, T., Hikiba, Y., Kanai, F., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., Kawakami, T., et al. (2003) · PubMed · Cited by 164
Colorectal carcinogenesis: Road maps to cancer
Worthley, D. L., Whitehall, V.-L., Spring, K.-J., & Leggett, B.-A. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i28.3784 · Cited by 154
Westra, J. L., Schaapveld, M., Hollema, H., de Boer, J. P., Kraak, M. M. J., de Jong, D., ter Elst, A., Mulder, N. H., Buys, C. H. C. M., Hofstra, R. M. W., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.096 · Cited by 137
Mutations in Both KRAS and BRAF May Contribute to the Methylator Phenotype in Colon Cancer
Nagasaka, T., Koi, M., Kloor, M., Gebert, J. F., Vilkin, A., Nishida, N., Shin, S. K., Sasamoto, H., Tanaka, N., Matsubara, N., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.094 · Cited by 130
p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer
Bouzourène, H., Gervaz, P., Cerottini, J., Benhattar, J., Chaubert, P., Saraga, E. P., Pampallona, S., Bosman, F. T., & Givel, J. C. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00036-8 · Cited by 117
Self-citationRusso, A. D., Bazan, V., Agnese, V., Rodolico, V., & Gebbia, V. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi907 · Cited by 109
Meta-analysis under the spotlight: Focused on a meta-analysis of ventilator weaning*
Tobin, M. J., & Jubran, A. (2008) · Critical Care Medicine · doi:10.1097/01.ccm.0000297883.04634.11 · Cited by 108
The Type of K-ras Mutation Determines Prognosis in Colorectal Cancer
Cerottini, J., Caplin, S., Saraga, E. P., Givel, J., & Benhattar, J. (1998) · The American Journal of Surgery · doi:10.1016/s0002-9610(97)00283-3 · Cited by 92
Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
Baselga, J. M., & Rosen, N. X. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3700 · Cited by 87
Wong, R., & Cunningham, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5024 · Cited by 84
Self-citationBazan, V., Agnese, V., Corsale, S., Calò, V., Valerio, M. R., Latteri, M. A., Vieni, S., Grassi, N., Cicero, G., Dardanoni, G., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi908 · Cited by 84
K-rasMutations and Prognosis in Large-Bowel Carcinomas
Andersen, S. N., Løvig, T., Breivik, J., Lund, E., Gaudernack, G., Meling, G., & Rognum, T. O. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709025065 · Cited by 70
Preto, A., Figueiredo, J., Velho, S., Ribeiro, A., Soares, P., Oliveíra, C., & Seruca, R. (2007) · The Journal of Pathology · doi:10.1002/path.2295 · Cited by 60
González-Aguilera, J. J., Oliart, S., Azcoita, M. M., & Fernández‐Peralta, A. M. (2004) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000045920.49210.7a · Cited by 38
Zauber, N. P., Wang, C., Lee, P. S., Redondo, T. C., Bishop, D. T., & Goel, A. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.017814 · Cited by 28
Research works printed but not linked: 1
- Ikenoue T, 2003, Cancer Res, 63, 8132
Cited by
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 4,974
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Self-citation
Metadata
- Authors
- Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Cisar, L., Labianca, R., Cunningham, D., Van Cutsem, E., & Bosman, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-20
- Volume
- 28
- Issue
- 3
- Pages
- 466-474
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2144026118
- Cited by
- 1,158
- References
- 35
- FWCI
- 34.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.